David A. Siegel Cytokinetics Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cytokinetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 214,700 shares of CYTK stock, worth $10.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

214,700

Holding current value

$10.7 Million

% of portfolio

0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $11 Million - $12.9 Million	214,700 New	214,700 $11.3 Million
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $4.9 Million - $8.3 Million	-76,800 Reduced 91.65%	7,000 $490,000
Q4 2023 Feb 14, 2024	SELL	$26.88 - $83.49 $2.5 Million - $7.77 Million	-93,100 Reduced 52.63%	83,800 $7 Million
Q3 2023 Nov 14, 2023	SELL	$29.46 - $36.61 $2.99 Million - $3.72 Million	-101,500 Reduced 36.46%	176,900 $5.21 Million
Q2 2023 Aug 14, 2023	SELL	$32.62 - $40.75 $5.83 Million - $7.28 Million	-178,600 Reduced 39.08%	278,400 $9.08 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $66,720 - $91,420	2,000 Added 0.44%	457,000 $16.1 Million
Q4 2022 Feb 14, 2023	BUY	$35.77 - $51.11 $1.9 Million - $2.71 Million	53,100 Added 13.21%	455,000 $20.8 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $2.41 Million - $3.41 Million	-62,500 Reduced 13.46%	401,900 $19.5 Million
Q2 2022 Aug 15, 2022	SELL	$33.93 - $48.92 $3.9 Million - $5.62 Million	-114,900 Reduced 19.83%	464,400 $18.2 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $5.94 Million - $9.19 Million	-199,800 Reduced 25.64%	579,300 $21.3 Million
Q4 2021 Feb 14, 2022	SELL	$34.35 - $46.38 $1.4 Million - $1.89 Million	-40,800 Reduced 4.98%	779,100 $35.5 Million
Q3 2021 Nov 15, 2021	SELL	$18.54 - $35.74 $1.06 Million - $2.04 Million	-57,100 Reduced 6.51%	819,900 $29.3 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $1.95 Million - $2.65 Million	-98,300 Reduced 10.08%	877,000 $17.4 Million
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $4.11 Million - $5.68 Million	221,200 Added 29.33%	975,300 $22.7 Million
Q4 2020 Feb 16, 2021	SELL	$15.26 - $28.61 $662,284 - $1.24 Million	-43,400 Reduced 5.44%	754,100 $15.7 Million
Q3 2020 Nov 16, 2020	BUY	$20.58 - $28.96 $1.45 Million - $2.04 Million	70,300 Added 9.67%	797,500 $17.3 Million
Q2 2020 Aug 14, 2020	BUY	$11.15 - $24.64 $595,410 - $1.32 Million	53,400 Added 7.93%	727,200 $17.1 Million
Q1 2020 May 15, 2020	BUY	$8.75 - $16.3 $1.34 Million - $2.49 Million	153,000 Added 29.38%	673,800 $7.94 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $11.84 $1.99 Million - $2.96 Million	250,000 Added 92.32%	520,800 $5.53 Million
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $154,726 - $203,775	14,300 Added 5.58%	270,800 $3.08 Million
Q2 2019 Aug 14, 2019	BUY	$7.95 - $11.25 $191,595 - $271,125	24,100 Added 10.37%	256,500 $2.89 Million
Q1 2019 May 15, 2019	BUY	$5.95 - $10.19 $1 Million - $1.72 Million	168,700 Added 264.84%	232,400 $1.88 Million
Q4 2018 Feb 14, 2019	SELL	$5.91 - $9.29 $18,912 - $29,727	-3,200 Reduced 4.78%	63,700 $403,000
Q3 2018 Nov 14, 2018	SELL	$6.4 - $9.85 $74,880 - $115,245	-11,700 Reduced 14.89%	66,900 $659,000
Q2 2018 Aug 14, 2018	SELL	$6.9 - $9.9 $37,260 - $53,460	-5,400 Reduced 6.43%	78,600 $652,000
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $66,240 - $92,460	9,200 Added 12.3%	84,000 $605,000
Q4 2017 Feb 14, 2018	BUY	$7.25 - $15.65 $208,800 - $450,720	28,800 Added 62.61%	74,800 $610,000
Q3 2017 Nov 14, 2017	BUY	$12.0 - $15.0 $552,000 - $690,000	46,000	46,000 $667,000

Others Institutions Holding CYTK

# of Institutions

410

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.69B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account